PRLD +20% in pre-mkt INCY - Prelude Therapeutics shares are higher in pre-mkt after Incyte discontinues further development of INCB160058. [
PRLD +20% in pre-mkt INCY - Prelude Therapeutics shares are higher in pre-mkt after Incyte discontinues further development of INCB160058. [Prelude Therapeutics' corresponding drug candidate is PRT12396, a mutant-selective JAK2V617F JH2 inhibitor that targets the same underlying myeloproliferative neoplasm (MPN) mechanism as Incyte's INCB160058.]
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.